Capricor Therapeutics (LTS:0HTB) ROCE %: -48.33% (As of Mar. 2026)


What is Capricor Therapeutics ROCE %?

Capricor Therapeutics LTS:0HTB 37 ROCE % is -48.33% as of Mar. 2026. GuruFocus rates LTS:0HTB with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Capricor Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2026 was -48.33%.

Capricor Therapeutics  (LTS:0HTB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Capricor Therapeutics ROCE % Related Terms

Capricor Therapeutics ROCE % Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics ROCE % Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -62.88 -96.76 -87.95 -46.03 -41.87

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.95 -90.36 -102.42 -44.02 -48.33

Capricor Therapeutics ROCE % Calculation

Capricor Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-87.105/( ( (162.809 - 20.08) + (303.98 - 30.605) )/ 2 )
=-87.105/( (142.729+273.375)/ 2 )
=-87.105/208.052
=-41.87 %

Capricor Therapeutics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-127.236/( ( (303.98 - 30.605) + (282.236 - 29.096) )/ 2 )
=-127.236/( ( 273.375 + 253.14 )/ 2 )
=-127.236/263.2575
=-48.33 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -48.33% mean?
Capricor Therapeutics (LTS:0HTB) has a ROCE % of -48.33% as of Mar. 2026.
Is Capricor Therapeutics' ROCE % too high?
Capricor Therapeutics' current ROCE % is -48.33%. Overall, Capricor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Capricor Therapeutics' ROCE % compare to COAG and DMRA?
Capricor Therapeutics' ROCE % of -48.33% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Capricor Therapeutics's current ROCE % is -48.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Capricor Therapeutics stock overvalued right now?
Capricor Therapeutics (LTS:0HTB) has a current ROCE % of -48.33%. The current ROCE % is -48.33%. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Capricor Therapeutics (LTS:0HTB), the current ROCE % is -48.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.